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Summary
Actinic keratoses (AKs) are common lesions in light-skinned individuals that can po-
tentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions 
may be associated with significant morbidity and constitute a major disease burden, 
especially among the elderly. To establish an evidence-based framework for clinical 
decision making, the guidelines for actinic keratosis and cutaneous squamous cell 
carcinoma were developed using the highest level of methodology (S3) according 
to regulations issued by the Association of Scientific Medical Societies in Germany 
(AWMF). The guidelines are aimed at dermatologists, general practitioners, ENT spe-
cialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and 
office-based settings as well as other medical specialties involved in the diagnosis and 
treatment of patients with AKs and cSCC. The guidelines are also aimed at affected pa-
tients, their relatives, policy makers and insurance funds. In the second part, we will 
address aspects relating to epidemiology, etiology, surgical and systemic treatment 
of cSCC, follow-up and disease prevention, and discuss AKs and cSCC in the context 
of occupational disease regulations. 
Table 1 Strength of consensus based on the percentage of 
agreement in the consensus process.
Strength of consensus Percentage of agreement
Strong consensus > 95 % of voters
Consensus > 75–95 % of voters
Majority approval > 50–75 % of voters
Dissent < 50 % of voters
Table 2 Gradation of the strengths of recommendations.
Grade of 
 recommendations
Description Wording
A Strong recommendation Shall
B Recommendation Should
0 Open recommendation Can
1 Introduction
The guideline represents a short version of the complete 
guidelines available as online supplement and at www.awmf 
.org. Information on “Diagnosis” and “Interventions for 
actinic keratoses” can be found in part 1 of the short version 
of the guideline or in the long version. A full list of references 
and the analysis of evidence underlying the recommenda-
tions and statements, along with the conflicts of interest of 
the authors involved in the present guidelines, are available 
in the long version and in the guideline report.
2 Methodology
At the launch event, the guideline group initially defined key 
questions. Following research required to address these ques-
tions, recommendations and statements were developed at the 
S3 level according to AWMF regulations. To classify the risk 
of bias pertaining to the relevant studies that were identified, 
the authors used the 2011 version of the Oxford Centre for 
Evidence-based Medicine system. Pursuant to AWMF regula-
tions, the methodology of the Oncology Guidelines Program 
of the German Cancer Society requires guideline authors to 
grade the recommendations as part of a formal consensus pro-
cedure. This included nominal group processes and structured 
consensus conferences moderated by AWMF representatives 
during which the recommendations were formally voted on 
by the mandate holders eligible to vote. Based on how many 
of them agreed with a given recommendation/statement, the 
strength of consensus was graded as shown in Table 1.
For each evidence-based statement and recommendati-
on, the level of evidence of the underlying studies is indicated 
in the guideline; recommendations also include an indication 
as to their strength (grade). Three grades of recommenda-
tions are distinguished herein, which is reflected by how the 
recommendations are worded (Table 2).
The criteria used for determining the grades of the re-
commendations are explained in the guideline report (see 
long version). Statements include presentations or explana-
tions of specific aspects or questions that do not immediately 
require any action. They are adopted in a formal consensus 
procedure, much in the same way as the recommendations; 
statements may be based either on study data or on expert 
opinions. Statements or recommendations that were consi-
dered to require modifications based on consensus of the 
experts involved are designated as “expert consensus”. No 
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symbols or letters were used for the gradation of “expert 
consensus” items; the strength of the various consensus 
points is reflected by the wording used (shall/should/can) 
(Table 2).
3 Epidemiology and etiology
3.1 Incidence
There is hardly any conclusive data on the epidemiology of 
AKs. Based on data from German statutory health insurance 
funds (2014) that included 90,800 employees, the prevalence 
among all age groups was calculated to be 2.7 % and showed 
an increase with age (11.5 % among 60–70-year-olds). Men 
were more commonly affected than women (3.9 % vs. 1.5 %).
The second most common type of skin cancer after basal 
cell carcinoma, cutaneous squamous cell carcinoma (cSCC) 
accounts for 20 % of all nonmelanoma skin cancer (NMSC) 
cases [1]. According to estimates by the Robert Koch Ins-
titute, roughly 29,300 men and 20,100 women in Germa-
ny developed cSCC for the first time in 2014 [2] (Figure 1, 
Table 3). It has been estimated that the incidence of cSCC 
in Germany has increased by a factor of four over the past 
30 years [1, 3, 4]. As patients with NMSC are predominantly 
treated in outpatient settings in Germany, it is safe to assume 
that the number of cases included in most cancer registries 
does not reflect the actual prevalence. Thus, the epidemiolo-
gical data available is incomplete, and the above-mentioned 
estimates are subject to a certain level of uncertainty. There is 
also limited international data, given that many countries do 
not include NMSC cases in their cancer registries.
As not all German federal states provide long-term data 
on the incidence of cSCC, we combined data considered to be 
conclusive from a number of different federal states – including 
Hamburg, Schleswig-Holstein, Bremen, Lower Saxony, Meck-
lenburg-Western Pomerania, Rhineland-Palatinate and the ad-
ministrative districts of Munster (North Rhine-Westphalia), 
Lower Bavaria and Upper Palatinate (Bavaria) [Table 3] – to 
calculate 10-year incidence rates for cSCC. Depending on the 
region, age-standardized incidence rates are currently between 
20/100,000 and 32/100,000 per year (age-standardized for 
the European standard population) (Table 4).
In 2016, 21 % of individuals aged 65 or older developed 
cSCC. Given the steady increase in the number of elder-
ly individuals in Germany, that figure is expected to rise. 
The number of over-65-year-olds is going to increase from 
17.4 million (2016) to approximately 20 million in 2025 
and will be associated with a corresponding uptick in cSCC 
incidence rates.
3.2 Mortality
Mortality rates for NMSC are low and have largely remained 
stable in Germany over the past 25 years. According to offi-
cial cause-of-death data, 464 men and 350 women died due 
to NMSC in 2015. The exact percentage of cSCC cases is 
unknown, as there is no specific ICD-10 code. Based on data 
from the federal statistics office, the mortality rate between 
2011 and 2015 was 0.65 for men and 0.3 for women, re-
spectively 0.62 and 0.27 between 1991 and 1995. Various 
publications have shown a low rate of disease-specific causes 
of death compared to general causes.
Figure 1 Raw incidence rates and extrapolated case numbers of cSCC in Germany in 2014.
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Table 3 Age-standardized incidence rates of cSCC in Germany between 2005 and 2014 (both genders), stratified by federal 
states and regions.
Incidence rates
2005–2009 2010–2014 Increase
Schleswig-Holstein 24.71 29.69 20 %
Hamburg 18.99 24.07 27 %
Lower Saxony 19.95 27.40 37 %
Bremen 21.59 21.67 0 %
Rhineland-Palatinate 26.41 32.09 22 %
Mecklenburg-Western Pomerania 15.39 21.63 41 %
Munster 16.15 24.45 51 %
Lower Bavaria 17.74 23.39 32 %
Upper Palatinate 17.66 20.91 18 %
All 9 regions combined 20.70 26.90 30 %
Table 4 Raw incidence rates and extrapolated case numbers in Germany in 2014.
Incidence
Raw rates, 2014 Population Extrapolated case numbers
9 regions Germany 2014
Male Female Male Female Male Female Total
0–4 0.00 0.21 1,768,121 1,679,831 0 4 4
5–9 0.00 0.00 1,790,922 1,699,097 0 0 0
10–14 0.00 0.18 1,912,951 1,813,657 0 3 3
15–19 0.16 0.00 2,085,232 1,968,411 3 0 3
20–24 0.14 0.30 2,371,714 2,252,466 3 7 10
25–29 0.27 0.00 2,615,697 2,490,930 7 0 7
30–34 0.28 1.45 2,550,763 2,484,263 7 36 43
35–39 1.35 1.06 2,374,936 2,338,925 32 25 57
40–44 3.86 3.36 2,687,988 2,646,102 104 89 193
45–49 7.68 7.14 3,444,916 3,357,094 265 240 504
50–54 14.83 12.85 3,415,839 3,366,917 507 433 939
55–59 26.97 22.24 2,870,852 2,900,161 774 645 1,419
60–64 55.94 32.28 2,489,668 2,634,296 1,393 850 2,243
65–69 119.47 63.49 1,904,860 2,061,785 2,276 1,309 3,585
70–74 258.11 111.99 2,113,109 2,432,159 5,454 2,724 8,178
75–79 421.01 180.48 1,760,828 2,242,693 7,413 4,048 11,461
80–84 593.03 262.97 928,610 1,418,596 5,507 3,730 9,237
85+ 726.43 373.79 609,191 1,498,933 4,425 5,603 10,028
Total 28,171 19,745 47,915
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3.3 Etiology and pathogenesis
The development of AKs is primarily caused by chronic ex-
posure to ultraviolet (UV) radiation, in particular to UVB. 
Numerous studies have demonstrated a correlation between 
the cumulative UV dose and the occurrence of AKs. UV ra-
diation induces mutations in the tumor suppressor gene p53, 
which is considered to be the causative event in the develop-
ment of AKs. The gene plays a key role in cell cycle regula-
tion and induces apoptosis in mutated cells. UVB radiation 
characteristically leads to the conversion of cytosine to thy-
mine in p53, resulting in a dysfunctional gene product (p53). 
Subsequently, this gives rise to uncontrolled proliferation of 
dysplastic cells and eventually to the development of AKs.
The etiology of cSCC is multifactorial. In addition to a 
genetic or immunological predisposition, it primarily invol-
ves exogenous factors, in particular UV radiation. Given its 
oncogenic potential, UV radiation was included in the hig-
hest cancer risk category (“carcinogenic to humans”) by the 
World Health Organization in 2009. With the newly estab-
lished occupational disease BK 5103 in Germany, cumulative 
“natural UV radiation” has been recognized as playing a key 
role in terms of cSCC development. Chemical carcinogens 
such as polycyclic aromatic hydrocarbons or arsenic are well 
established carcinogens involved in the induction of cSCC.
3.4 Risk factor immunosuppression
A typical long-term complication of chronic immunosup-
pression, epithelial skin tumors are by far the most common 
malignant neoplasms among organ transplant recipients 
(OTRs). Similarly, these individuals also show a significant-
ly higher risk of developing AKs. The incidence of NMSC 
increases with the number of years of immunosuppression 
and is 40–60 % after 20 years. In addition, AKs exhibit a 
much more aggressive growth behavior in OTRs, with early 
progression to cSCC.
3.5  Prognostic factors for the progression of AKs 
to cSCC
Consensus-based statement
Expert consensus The data currently available with 
 respect to prognostic factors for 
the progression of AKs to cSCC 
is  insufficient. At present, it is 
 impossible to reliably quantify the 
likelihood of disease progression from 
AKs to SCC.
Strong consensus (100 %)
Consensus-based recommendation
Expert consensus Given that existing clinical and his-
tological classification systems (e.g., 
Olsen classification; keratinocyte in-
traepithelial neoplasia 1–3) have not 
been sufficiently validated in terms 
of their prognostic significance, new 
classifications should be developed.
Strong consensus (100 %)
3.6  Prognostic factors for the development of 
cSCC-related metastasis
Evidence-based recommendation
Grade of recom-
mendation 0
Prognostic factors for metastatic 
spread or disease-specific survival 
include histopathological (depth 
of vertical tumor infiltration, des-
moplasia, degree of differentiation, 
perineural growth) and clinical as-
pects (site, horizontal tumor extent, 
comorbidities such as immunosup-
pression).
Level of evidence 4 De novo research
Strong consensus (100 %)
Prognostic factors for metastatic spread and disease-spe-
cific survival in patients with cSCC include the following:
 vertical tumor thickness (> 6 mm),
 horizontal tumor extent (≥ 2 cm),
 histological differentiation (> grade 3),
 desmoplasia,
 perineural growth,
 site (lower lip, ear),
 immunosuppression (iatrogenic or disease-related).
The aforementioned risk factors apply to the sections 
“Diagnosis” (short version – part 1), “Surgical and systemic 
treatment of cSCC” (short version – part 2) and “Follow-up” 
(short version – part 2).
4 Surgical and systemic treatment of cSCC
4.1 Surgical treatment of the primary tumor
Consensus-based recommendation
Expert consensus Standard treatment shall consist of 
histologically controlled excision.
Strong consensus (100 %)
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Consensus-based recommendation
Expert consensus The goal of cSCC surgery shall be 
complete excision (R0) with histolo-
gical evaluation of both peripheral 
and deep margins. If the diagnosis is 
clinically straightforward, excisional 
biopsy or therapeutic excision with 
sufficient surgical margins can be 
performed.
Strong consensus (100 %)
Although there is no dispute in the literature that surgi-
cal excision is the treatment of choice for cSCC, there is little 
consensus as to the exact surgical approach and the subse-
quent histological examination. In this context, the degree 
of accuracy employed for histological control of excision 
margins has a significant impact on the surgical approach. 
Detailed information on surgical removal options for cSCC 
can be found in the long version.
Consensus-based statement
Expert consensus Horizontal ablation (deep “shave” 
 excision) is an alternative approach 
for small tumors.
Consensus (76.1 %)
When using horizontal ablation (shave excision) for the 
removal of small tumors, it is essential that dermatopatholo-
gist be provided with sufficient tissue to perform a conclusi-
ve histological examination. There are no published studies 
on this topic. The specimen should be no less than 5 mm in 
diameter and include the deep dermis or even the upper sub-
cutis. If the tumor was thus removed completely, subsequent 
secondary intention healing will lead to very good aesthetic 
outcomes. For larger and thicker tumors, the specimen shall 
include deeper layers of the subcutis (approximately 6 mm 
deep, if possible). This enables the dermatopathologist to 
evaluate both tumor thickness and differentiation and thus 
allows for a fairly accurate prognostic assessment.
Consensus-based recommendation
Expert consensus As long as there is no histological con-
firmation that the tumor has been exci-
sed completely (R0 resection), wound 
closure shall only be performed if the 
resection margins can be unequivocal-
ly identified postoperatively (e.g., no 
advancement flaps).
Strong consensus (100 %)
For very large tumors or those at unfavorable sites, recon-
structive wound closure is not recommended until it has been 
confirmed that the resection margins are tumor free. This is 
especially true when local flaps are planned, as this may lead 
to displacement of resection margins, which complicates their 
subsequent identification if re-excision is required.
4.2 Sentinel lymph node biopsy (SLNB)
Evidence-based statement
Level of evidence 3 There is currently no valid data 
regarding the prognostic and 
 therapeutic significance of SLNB.
De novo research
Strong consensus (100 %)
Given that there is currently no sufficient and valid data 
regarding the prognostic and therapeutic value of SLNB, a 
general recommendation for this procedure cannot be issued 
[5–9]. Previous studies failed to demonstrate any statistically 
significant benefit of SLNB in terms of disease-specific and 
overall survival as well as metastasis-free survival [10]. Most 
of the data available refers to the use of SLNB in high-risk 
settings. Numerous studies suggest that there is a potential 
benefit (detection of clinically occult micrometastases, avoi-
dance of unnecessarily extensive lymphadenectomies [with 
higher morbidity than SLNB]) in patients with high-risk 
cSCC, which is associated with a metastatic risk of > 10 %. 
SLNB-related complications are rare (3–5 %) and inclu-
de lymphedema, infection, hematoma, seroma, cutaneous 
lymphatic fistula and wound dehiscence.
4.3  Prophylactic and therapeutic 
lymphadenectomy
Evidence-based recom-
mendation
Grade of recommendation 
A
Prophylactic lympha-
denectomy shall not be 
performed. There is cur-
rently  insufficient data 
regarding the value of 
regional lymphadenectomy 
 following positive SLNB.
Level of evidence 3 De novo research
Strong consensus (100 %)
For cSCC, there is as yet no evidence for a (prospecti-
ve) benefit of prophylactic (elective) lymph node dissection in 
terms of disease-specific and overall survival [11, 12].
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Evidence-based recommendation
Grade of recom-
mendation B
Regional (therapeutic) lympha-
denectomy should be performed in 
cases of clinically manifest lymph 
node metastasis.
Level of evidence 3 De novo research
Strong consensus (100 %)
Evidence-based statement
Level of evidence 3 It has been reported that regional 
therapeutic lymphadenectomy in 
patients with lymph node metastasis 
is associated with improved locoregi-
onal disease control.
De novo research
Strong consensus (100 %)
Therapeutic lymph node dissection shall only be perfor-
med if such an approach is feasible and warranted by the pa-
tient’s general health (general operability) and if it is deemed 
reasonable within the overall treatment concept. This requi-
res that the metastasis can be completely (R0) resected (local 
operability). If neither general nor local operability are ensu-
red, non-surgical treatment modalities should be given pre-
ference as determined by an interdisciplinary tumor board.
4.4 Lymphadenectomy in the head and neck region
Evidence-based statement
Level of evidence 3 There is no general consensus regar-
ding the required level of dissection 
in the head and neck region.
De novo research
Strong consensus (100 %)
There is no consensus in the literature regarding the requi-
red extent of lymph node dissection in the head and neck regi-
on. Especially the site of the primary tumor plays a key role. A 
few sites are known to be fairly consistently associated with a 
certain lymphatic drainage pathway. For example, the lower lip 
drains into the submental, submandibular and upper cervical 
lymph nodes (levels Ia, Ib and II according to Robbins et al. [13]) 
[14–16]. If feasible, selective functional neck dissection should 
be performed, as this approach spares functionally vital structu-
res (especially nerves, muscles and vessels). Radical dissections 
are only recommended for patients with extensive metastatic 
disease, due to the greater morbidity associated with these pro-
cedures. Similar to the results observed in the treatment of car-
cinoma of the oral cavity, the outcomes achieved with selective 
neck dissection in terms of tumor control, disease-specific and 
overall survival are not inferior to those achieved with modified 
radical or radical neck dissection (modified after the “S3 guide-
lines for Carcinoma of the Oral Cavity”) [17–20].
4.5 Adjuvant and postoperative radiation therapy
Evidence-based recommendation
Grade of recom-
mendation B
Radiation therapy should be per-
formed in patients with locally not 
completely resectable or inoperable 
disease.
Level of evidence 3 De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation B
Postoperative radiation therapy 
should be performed in cases of:
– R1 or R2 resection (if re-excision 
is not feasible)
– Extensive lymph node invol-
vement (> 1 affected lymph 
node, lymph node metastasis 
> 3 cm, capsular penetration)
– Intraparotid lymph node 
 involvement
Level of evidence 2 De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation B
Adjuvant radiation therapy should 
be performed in the presence of the 
following risk factors:
– Surgical margins < 2 mm and 
re-excision is not feasible
– Extensive perineural infiltration
Level of evidence 2 De novo research
Strong consensus (100 %)
While there is no general indication for postoperative 
radiation therapy in patients with cSCC, it should be offered 
to individuals with risk factors for local or locoregional re-
currence. Such risk factors (which have been subject to cont-
roversial debate) include R1 or R2 resection, narrow surgical 
margins (< 2 mm, and re-excision is not feasible), recurrent 
tumor, maximum tumor size (> 2 cm), maximum tumor in-
vasion (> 4 mm), infiltration of subcutaneous tissue, perineu-
ral and extensive lymphatic involvement (> 1 affected lymph 
node, capsular penetration).
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Mandatory indications for postoperative radiation the-
rapy include R1 or R2 resection as well as cases in which 
re-excision is not feasible following resection with narrow 
surgical margins (< 2 mm). In the presence of risk factors, 
postoperative radiation therapy can be combined with plati-
num-based chemotherapy [21, 22].
4.6 Treatment of local or locoregional recurrence
Consensus-based recommendation
Expert consensus If clinically feasible, recurrent loco-
regional disease shall be managed 
surgically.
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation A
Micrographically controlled surgery 
(MCS) shall be employed for this 
purpose.
Level of evidence 2 De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation B
If, over the course of the resection, 
there is evidence of residual, unre-
sectable tumor tissue (R1 or R2 resec-
tion), radiation therapy of the area 
thus affected should be performed.
Level of evidence 2 De novo research
Strong consensus (100 %)
Evidence-based recommendation
Grade of recom-
mendation B
In case of inoperability as deter-
mined by an interdisciplinary tumor 
board, radiation therapy should be 
performed.
Level of evidence 3 De novo research
Strong consensus (100 %)
Consensus-based recommendation
Expert consensus The indication for electrochemothe-
rapy or systemic treatment should be 
reviewed in patients with recurrent 
local or locoregional disease if no 
surgical or radiation therapy options 
are available.
Consensus (93.3 %)
Local recurrences frequently exhibit a more extensive, 
irregular subclinical infiltration pattern than primary tu-
mors, a phenomenon that is difficult to completely assess 
using conventional bread-loaf sections. Local recurrences 
in the head and neck region are very often desmoplastic 
lesions that are characterized by high recurrence rates even 
following MCS [23, 24]. It is not uncommon for patients 
with this tumor type to die from complications caused by 
local tumor infiltration [25]. It is therefore recommended 
that patients with recurrent disease following MCS under-
go postoperative radiation therapy. Studies have shown 
that this approach reduces recurrence rates and is associa-
ted with longer recurrence-free survival than surgery alone 
[7, 21, 26–32].
Patients with inoperable disease for whom radiation the-
rapy is not feasible can be treated with electrochemotherapy 
to improve local tumor control; the overall response rate has 
been reported to be 46 % [33–35]. In addition, the indication 
for systemic treatment should be reviewed.
4.7  Systemic treatment for distant metastatic 
disease
Consensus-based recommendation
Expert consensus There are no controlled or randomi-
zed studies on the benefit of systemic 
treatment for metastatic SCC. If used, 
systemic treatment should preferably 
be administered in the context of 
 clinical trials.
The decision to administer systemic 
treatment and the choice thereof 
should be made by an interdiscipli-
nary tumor board.
Strong consensus (100 %)
Cutaneous SCC is chemosensitive and shows response 
rates > 50 % to platinum-based chemotherapy. While res-
ponse rates are higher with polychemotherapy or chemoradi-
ation therapy, the duration of the response remains unclear, 
and polychemotherapy regimens are likely associated with 
greater toxicity. Monotherapy with epidermal growth factor 
receptor (EGFR) inhibitors has achieved response rates bet-
ween 25 % and 45 %.
A novel therapeutic approach for inoperable cSCC, 
PD1 inhibitors have been shown to be effective in tumor 
entities characterized by a high mutational burden (which 
is a feature of cSCC). Initial data from a study investigating 
the anti-PD1 antibody cemiplimab showed response rates 
of 47–50 %; after a median follow-up of 7.9 months, the 
median duration of response had not been reached. At that 
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time, 82 % of patients who had a response continued to 
have a response [36].
Patients with advanced or metastatic cSCC are typically 
older and have relevant comorbidities; for example, chronic 
lymphocytic leukemia is a risk factor for rapid disease pro-
gression in patients with cSCC. Irrespective of age, OTRs on 
immunosuppressive medication should be mentioned in this 
context. While several studies have shown that switching to a 
regimen that includes an mTOR inhibitor has positive effects 
in terms of primary and secondary prevention of new epithe-
lial skin cancers in kidney transplant recipients, it remains 
to be elucidated whether switching to mTOR inhibitors has 
any effect on clinically manifest epithelial skin cancer lesions 
[37–40].
In summary, no treatment recommendation can be given 
at this time. It is recommended to administer any systemic 
treatment in the context of clinically controlled trials. If this 
is not feasible, options to be considered include chemothe-
rapeutic agents, EGFR inhibitors and/or immunotherapeutic 
agents; any comorbidities and the patient’s overall health 
should be observed.
5 Follow-up
5.1 Follow-up intervals
In order to detect disease recurrence and secondary tumors 
at an early stage, it is recommended that cSCC patients un-
dergo risk-adapted follow-up. It is estimated that 30–50 % 
of secondary cSCC lesions occur within one year after the 
diagnosis of the primary tumor. While the risk is highest 
within the first four years after the initial diagnosis, it 
is still significantly increased after 15 years of follow-up 
[41]. The development of independent secondary tumors is 
a common problem, especially in high-risk patients such 
as individuals with field cancerization of the face, hands 
and balding scalp as well as OTRs on long-term immuno-
suppressive medication. Given that approximately 80 % of 
recurrences occur within the first two years after the initial 
diagnosis, particularly close follow-up is recommended du-
ring this period.
Consensus-based recommendation
Expert consensus Risk-adapted follow-up should be offered to patients with cSCC* based on the following schedule:
Year 1–2 Year 3–5 Year 6–10
Low-to-medium risk Every 6 months Annually –
High risk Every 3 months Every 6 months Annually
*for completely resected tumors (R0).
Strong consensus (100 %).
5.2 Examination methods
5.2.1 Clinical examination
Consensus-based recommendation
Expert consensus All patients with cSCC shall undergo 
clinical follow-up examinations on a 
regular basis, including inspection of 
the entire skin as well as inspection 
and palpation of the primary resecti-
on site, the in-transit pathway and the 
regional lymph node basin.
Strong consensus (100 %)
5.2.2 Lymph node ultrasound
Consensus-based recommendation
Expert consensus Lymph node ultrasound should be per-
formed in patients at increased risk of 
metastasis and in cases in which palpa-
tion has yielded ambiguous findings.
Strong consensus (100 %)
5.2.3 Chest X-ray and abdominal ultrasound
Consensus-based recommendation
Expert consensus Routine chest X-ray should not be 
performed during follow-up. Routine 
abdominal ultrasound should not be 
performed during follow-up.
Strong consensus (100 %)
5.2.4 Cross-sectional imaging
Consensus-based recommendation
Expert 
 consensus
Cross-sectional imaging should be used 
in the workup of recurrent disease, for ex-
ample, if functional structures are suspec-
ted to be affected or if perineural tumor 
growth or metastasis are suspected.
Strong consensus (100 %)
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Overall, the data currently available does not allow for a 
general recommendation to be made with respect to the vari-
ous imaging techniques, as there are no studies investigating 
their use specifically in patients with cSCC. Given that there 
are no studies on the routine use of cross-sectional imaging in 
the follow-up of cSCC, these modalities are reserved for the 
workup of suspected metastasis. The choice of cross-sectional 
imaging modality in this context is guided by practical and 
economical aspects as well as the body region to be examined.
6 Prevention
See sections 4 (primary prevention) and 5 (secondary preven-
tion) of the “S3 guidelines for the Prevention of Skin Cancer” 
[42]. As the topics “chemoprevention”, “photodynamic the-
rapy”, “retinoids” and “nicotinamide” were not addressed 
in that particular publication, they are discussed in the long 
version of the present guidelines.
7 AKs and cSCC as occupational disease
7.1  Diagnostic workup and reporting of 
suspected occupational skin cancer
With the amendment of the German Occupational Disease 
Regulation on January 1, 2015, occupational disease BK 
5103 (“SCC or multiple AKs of the skin caused by natural 
UV radiation”) was newly included in the list of officially 
recognized occupational diseases (Table 5). The term “mul-
tiple” is defined either as the development of more than five 
individual AKs within a period of twelve months or as the 
presence of field cancerization involving more than 4 cm2. Bo-
wen’s disease and Bowen’s carcinoma are likewise recognized 
skin cancer entities pursuant to the requirements of BK 5103. 
With respect to its biological behavior and its status in terms 
of insurance law, extra genital Bowen’s disease is considered 
to be equivalent to AKs. Thus, recognition as occupational 
Table 5 Requirements that must be met for disease recognition pursuant to BK 5103 (“cSCC or multiple AKs of the skin caused 
by natural UV radiation”).
Criterion Description
Skin tumor site Lesions must arise in areas affected by occupational exposure to UV radiation (in this context, 
consider whether patients with skin tumors of the scalp were protective gear, such as a hardhat, 
at work).
Confirmed clinical 
 diagnosis
Cutaneous SCC (histologically confirmed) or at least 6 individual AKs diagnosed on clinical 
grounds within a period of 12 months (histological confirmation of one AK is recommended) or 
confluent AKs involving an area of at least 4 cm2 (field cancerization).
Extragenital Bowen’s disease is considered to be equivalent to AKs; Bowen’s carcinoma to cSCC.
Signs of chronic UV- 
induced skin damage/ 
which sites are involved?
Chronic UV- induced skin damage is not a sine qua non for recognition as occupational disease.
However, the severity and distribution of UV- induced damage (occupationally vs. non- 
occupationally exposed skin areas) provide important clues as to causation.
Skin phototype 
( Fitzpatrick)
Does generally not play a role for recognition as occupational disease but should always be spe-
cified in the occupational disease report.
The skin phototype is an essential risk factor for the development of skin cancer. It is  modified 
by both occupational and non-occupational exposure to UV radiation and  affects the time of 
disease onset.
Non-occupational risk 
factors
It should be specified whether there is evidence for other non-occupational risk factors, 
 including immunosuppression, drugs that increase photosensitivity, phototherapy, pigmentary 
disorders, impaired DNA repair capability, exposure to carcinogens, and others.
Additional occupational 
UV exposure of at least 
40 %.
A rough estimate is sufficient for physicians to file an occupational disease report. Actual quanti-
fication of occupational UV exposure is done by concrete calculations by the Prevention Services 
of the competent statutory accident insurance company.
Information whether the 
patient’s vacation and 
leisure behavior differs 
 significantly from that of 
the general  population
The calculations done by the Prevention Services assume an average non-occupational UV expo-
sure of the general population of 130 SED (standard erythema dose; 1 SED = 100 J/m2) per year. 
Significant deviations due to the patient’s individual vacation and leisure  behavior should be 
specified.
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disease requires multiple such lesions or involvement of an 
area ≥ 4 cm2. Following its potential progression to Bowen’s 
carcinoma, the condition is considered to be (legally) equiva-
lent to cSCC. While the diagnosis of cSCC requires histologi-
cal confirmation in order to be legally recognized, this is not 
the case for multiple AKs, which may be diagnosed merely on 
clinical grounds. Nevertheless, it is recommended to provide 
a pathology report for at least one of the existing AKs and to 
attach it to the occupational disease notification.
Detailed information on the diagnosis and reporting of 
occupational cSCC and AKs can be found in the long version 
of the guideline.
7.2  Prevention of occupational skin cancer 
caused by UV radiation
Primary prevention measures are paramount. Pursuant to 
Section 3 of the German Labor Protection Act (ArbSchG), 
it is the employer’s responsibility to institute appropriate 
protective measures. Not only does this apply to hazardous 
materials and substances at the workplace but also to ha-
zards caused by UV radiation from the sun (Table 6). With 
the revision of the German Ordinance on Preventive Occu-
pational Health Care (ArbMedVV) currently underway, it is 
intended to ensure that individuals who work outdoors on 
a regular basis will both be required to undergo mandato-
ry screening and also have the opportunity for voluntary 
screening exams. In addition, the guidelines for “Prevention 
of Occupational Skin Cancer” currently being developed will 
provide evidence- and consensus-based recommendations for 
primary, secondary and tertiary prevention of skin cancer 
pursuant to BK 5103.
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